Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study
Study limitation reported by the research below: “Patients were not stratified by age subgroup within 'paediatric,' so it is unclear how findings apply to younger children vs. adolescents specifically.”